ArticleJournal of virology2005
In vitro and in vivo mutational analysis of the 3'-terminal regions of hepatitis e virus genomes and replicons.
Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 69 citations in OpenAlex.
- Research Progress on Hepatitis E Virus Culture.Pathogens (Basel, Switzerland) · 2025Review
- Development of a HiBiT-tagged reporter hepatitis E virus and its utility as an antiviral drug screening platform.Journal of virology · 2023Article
- Expanding the Hepatitis E Virus Toolbox: Selectable Replicons and Recombinant Reporter Genomes.Viruses · 2023Review
- Article
- HEV Cell Culture.Advances in experimental medicine and biology · 2023Article
- The Capsid (ORF2) Protein of Hepatitis E Virus in Feces Is C-Terminally Truncated.Pathogens (Basel, Switzerland) · 2021Article
- RNA Helicase A Regulates the Replication of RNA Viruses.Viruses · 2021Review
- Review
- Hepatitis E Virus: How It Escapes Host Innate Immunity.Vaccines · 2020Review
- Hepatitis E virus infection during pregnancy.Virology journal · 2020Review
- Identification of functional cis-acting RNA elements in the hepatitis E virus genome required for viral replication.PLoS pathogens · 2020Article
- Hepatitis E Virus Replication.Viruses · 2019Review
- Antiviral Candidates for Treating Hepatitis E Virus Infection.Antimicrobial agents and chemotherapy · 2019Article
- Hepatitis E Virus Genome Structure and Replication Strategy.Cold Spring Harbor perspectives in medicine · 2019Review
- Origin, antigenicity, and function of a secreted form of ORF2 in hepatitis E virus infection.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Hepatitis E Virus Mutations: Functional and Clinical Relevance.EBioMedicine · 2016Review
- Innate immune responses in human hepatocyte-derived cell lines alter genotype 1 hepatitis E virus replication efficiencies.Scientific reports · 2016Article
- Therapeutic targets for the treatment of hepatitis E virus infection.Expert opinion on therapeutic targets · 2015Review
- Mapping overlapping functional elements embedded within the protein-coding regions of RNA viruses.Nucleic acids research · 2014Article
- Hepatitis E virus inhibits type I interferon induction by ORF1 products.Journal of virology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Hepatitis E virus (HEV) replication is not well understood, mainly because the virus does not infect cultured cells efficiently. However, Huh-7 cells transfected with full-length genomes produce open reading frame 2 protein, indicative of genome replication (6). To investigate the role of 3'-terminal sequences in RNA replication, we constructed chimeric full-length genomes with divergent 3'-terminal sequences of genotypes 2 and 3 replacing that of genotype 1 and transfected them into Huh-7 cells. The production of viral proteins by these full-length chimeras was indistinguishable from that of the wild type, suggesting that replication was not impaired. In order to better quantify HEV replication in cell culture, we constructed an HEV replicon with a reporter (luciferase). Luciferase production was cap dependent and RNA-dependent RNA polymerase dependent and increased following transfection of Huh-7 cells. Replicons harboring the 3'-terminal intergenotypic chimera sequences were also assayed for luciferase production. In spite of the large sequence differences among the 3' termini of the viruses, replication of the chimeric replicons was surprisingly similar to that of the parental replicon. However, a single unique nucleotide change within a predicted stem structure at the 3' terminus substantially reduced the efficiency of replication: RNA replication was partially restored by a covariant mutation. Similar patterns of replication were obtained when full-length genomes were inoculated into rhesus macaques, suggesting that the in vitro system could be used to predict the effect of 3'-terminal mutations in vivo. Incorporation of the 3'-terminal sequences of the swine strain of HEV into the genotype 1 human strain did not enable the human strain to infect swine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.